Please wait a minute...
Shopping Cart Email List Chinese
Advanced Search Fig/Tab
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Featured Articles  |  Most Downloaded  |  Most Reading
Online Submission Subscribe to Our RSS Content Feed
Front. Med.    2022, Vol. 16 Issue (4) : 661-664    https://doi.org/10.1007/s11684-021-0907-9
CORRESPONDENCE
Answer for questions of repeated measurements of variance analysis and distribution test of data — Authors’ reply
Dao Wen Wang1(), Li Ni1, Hualiang Jiang2,3
1. Division of Cardiology, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2. State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
3. Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China
 Download: PDF(263 KB)   HTML
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Corresponding Author(s): Dao Wen Wang   
About author:

Tongcan Cui and Yizhe Hou contributed equally to this work.
Just Accepted Date: 25 May 2022   Online First Date: 30 June 2022    Issue Date: 02 September 2022
 Cite this article:   
Dao Wen Wang,Li Ni,Hualiang Jiang. Answer for questions of repeated measurements of variance analysis and distribution test of data — Authors’ reply[J]. Front. Med., 2022, 16(4): 661-664.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-021-0907-9
https://academic.hep.com.cn/fmd/EN/Y2022/V16/I4/661
F-statistic P value
Intervention Control vs. low dose vs. mid dose vs. high dose 0.795 0.498
Time Day 0 vs. 2 vs. 4 vs. 7 vs. 10 vs. 14 71.185 < 0.001
Interaction Time & intervention 1.630 0.134
Tab.1  The interaction between interventions and time in effects of SHL treatment on the symptoms scores as compared with standard care
F-statistic P value
Intervention Standard care vs. combined dose groups 1.749 0.190
Time Day 7 vs. day 14 8.285 0.005
Interaction Time & intervention 0.722 0.398
Intervention Control vs. low dose vs. mid dose vs. high dose 2.795 0.05
Time Day 7 vs. day 14 15.02 < 0.001
Interaction Time & intervention 0.943 0.424
Tab.2  The interaction between interventions and time in reduction of density of infection focus on CT imaging from baseline
F-statistic P value
IL-6
Intervention Standard care vs. combined dose groups 2.234 0.157
Time Day 0 vs. day 7 vs. day 14 1.686 0.215
Interaction Time & intervention 0.766 0.401
Intervention Control vs. low dose vs. mid dose vs. high dose 0.738 0.550
Time Day 0 vs. day 7 vs. day 14 3.992 0.066
Interaction Time & intervention 1.427 0.281
IL-8
Intervention Standard care vs. combined dose groups 0.033 0.859
Time Day 0 vs. day 7 vs. day 14 4.640 0.018
Interaction Time & intervention 0.700 0.505
Intervention Control vs. low dose vs. mid dose vs. high dose 0.306 0.820
Time Day 0 vs. day 7 vs. day 14 3.068 0.065
Interaction Time & intervention 0.389 0.879
IL-10
Intervention Standard care vs. combined dose groups 0.353 0.562
Time Day 0 vs. day 7 vs. day 14 1.275 0.295
Interaction Time & intervention 0.078 0.925
Intervention Control vs. low dose vs. mid dose vs. high dose 1.062 0.402
Time Day 0 vs. day 7 vs. day 14 0.903 0.419
Interaction Time & intervention 0.238 0.959
TNF-α
Intervention Standard care vs. combined dose groups 0.074 0.789
Time Day 0 vs. day 7 vs. day 14 0.099 0.906
Interaction Time & intervention 0.122 0.886
Intervention Control vs. low dose vs. mid dose vs. high dose 0.925 0.458
Time Day 0 vs. day 7 vs. day 14 0.171 0.844
Interaction Time & intervention 0.149 0.987
IL-1b
Intervention Standard care vs. combined dose groups 0.031 0.863
Time Day 0 vs. day 7 vs. day 14 0.503 0.526
Interaction Time & intervention 0.877 0.384
Intervention Control vs. low dose vs. mid dose vs. high dose 0.704 0.568
Time Day 0 vs. day 7 vs. day 14 0.265 0.660
Interaction Time & intervention 0.737 0.570
IL-2R
Intervention Standard care vs. combined dose groups 1.311 0.271
Time Day 0 vs. day 7 vs. day 14 1.434 0.255
Interaction Time & intervention 1.762 0.204
Intervention Control vs. low dose vs. mid dose vs. high dose 1.238 0.339
Time Day 0 vs. day 7 vs. day 14 2.547 0.127
Interaction Time & intervention 0.625 0.641
Tab.3  The interaction between interventions and time in the analysis of serum inflammatory factors
F-statistic P value
NT-proBNP
Intervention Standard care vs. combined dose groups 1.898 0.180
Time Day 0 vs. day 7 vs. day 14 1.524 0.230
Interaction Time & intervention 1.909 0.170
Intervention Control vs. low dose vs. mid dose vs. high dose 0.588 0.629
Time Day 0 vs. day 7 vs. day 14 0.348 0.638
Interaction Time & intervention 0.823 0.527
cTnI
Intervention Standard care vs. combined dose groups 0.445 0.509
Time Day 0 vs. day 7 vs. day 14 0.466 0.500
Interaction Time & intervention 0.419 0.523
Intervention Control vs. low dose vs. mid dose vs. high dose 0.607 0.616
Time Day 0 vs. day 7 vs. day 14 0.684 0.415
Interaction Time & intervention 0.644 0.593
Tab.4  The interaction between interventions and time in the analysis of markers of myocardial injury
F-statistic P value
IgM
Intervention Standard care vs. combined dose groups 0.026 0.873
Time Day 0 vs. day 7 vs. day 14 1.523 0.234
Interaction Time & intervention 0.470 0.518
Intervention Control vs. low dose vs. mid dose vs. high dose 1.605 0.227
Time Day 0 vs. day 7 vs. day 14 4.169 0.052
Interaction Time & intervention 1.891 0.163
IgG
Intervention Standard care vs. combined dose groups 5.831 0.027
Time Day 0 vs. day 7 vs. day 14 5.039 0.032
Interaction Time & intervention 1.232 0.287
Intervention Control vs. low dose vs. mid dose vs. high dose 1.871 0.175
Time Day 0 vs. day 7 vs. day 14 3.596 0.070
Interaction Time & intervention 0.735 0.560
Tab.5  The interaction between interventions and time in the analysis of antibodies of SARS-CoV-2
Kolmogorov–Smirnova Shapiro–Wilk
Statistic P value Statistic P value
Age 0.067 0.017 0.974 < 0.001
Onset day 0.137 < 0.001 0.947 < 0.001
temp 0.126 < 0.001 0.926 < 0.001
SBP 0.108 < 0.001 0.972 < 0.001
HR 0.121 < 0.001 0.960 < 0.001
RR 0.239 < 0.001 0.797 < 0.001
WBC 0.132 < 0.001 0.932 < 0.001
Lymph 0.062 0.041 0.969 < 0.001
PLT 0.096 < 0.001 0.909 < 0.001
ALT 0.242 < 0.001 0.568 < 0.001
AST 0.260 < 0.001 0.412 < 0.001
Crea 0.095 < 0.001 0.906 < 0.001
LDH 0.174 < 0.001 0.739 < 0.001
TBIL 0.133 < 0.001 0.844 < 0.001
PT 0.273 < 0.001 0.320 < 0.001
Tab.6  Tests of normality for the continuous data of characteristics at baseline
Kolmogorov–Smirnova Shapiro–Wilk
Statistic P value Statistic P value
IL-6_0 d 0.275 0.002 0.730 < 0.001
IL-10_0 d 0.433 < 0.001 0.566 < 0.001
IL-8_0 d 0.165 0.200* 0.933 0.275
TNF-α_0 d 0.156 0.200* 0.955 0.579
IL-1b_0 d 0.378 < 0.001 0.580 < 0.001
IL-2R_0 d 0.160 0.200* 0.843 0.011
IL-6_7 d 0.273 0.002 0.763 0.001
IL-10_7 d 0.496 < 0.001 0.358 < 0.001
IL-8_7 d 0.178 0.187 0.902 0.086
TNF-α_7 d 0.215 0.046 0.895 0.068
IL-1b_7 d 0.331 < 0.001 0.697 < 0.001
IL-2R_7 d 0.124 0.200* 0.942 0.373
IL-6_14 d 0.298 < 0.001 0.690 < 0.001
IL-10_14 d 0.424 < 0.001 0.318 < 0.001
IL-8_14 d 0.153 0.200* 0.901 0.082
TNF-α_14 d 0.183 0.156 0.879 0.037
IL-1b_14 d 0.507 < 0.001 0.285 < 0.001
IL-2R_14 d 0.135 0.200* 0.944 0.406
Tab.7  Tests of normality for the continuous data of serum inflammatory factors
Kolmogorov–Smirnova Shapiro–Wilk
Statistic P value Statistic P value
NTproBNP_0 d 0.220 0.005 0.843 0.002
NTproBNP_7 d 0.278 < 0.001 0.590 < 0.001
NTproBNP_14 d 0.286 < 0.001 0.671 < 0.001
cTnI_0 d 0.343 < 0.001 0.578 < 0.001
cTnI_7 d 0.223 0.004 0.776 < 0.001
cTnI_14 d 0.340 < 0.001 0.531 < 0.001
CRP_0 d 0.310 < 0.001 0.550 < 0.001
CRP_7 d 0.289 < 0.001 0.602 < 0.001
CRP_14 d 0.334 < 0.001 0.534 < 0.001
Tab.8  Tests of normality for the continuous data of markers of myocardial injury
Kolmogorov–Smirnova Shapiro–Wilk
Statistic P value Statistic P value
IgM_0 d 0.373 < 0.001 0.373 < 0.001
IgG_0 d 0.120 0.200* 0.918 0.089
IgM_7 d 0.381 < 0.001 0.487 < 0.001
IgG_7 d 0.237 0.005 0.858 0.007
IgM_14 d 0.406 < 0.001 0.424 < 0.001
IgG_14 d 0.218 0.014 0.896 0.034
Tab.9  Tests of normality for the continuous data of antibodies of SARS-CoV-2
1 L Ni, Z Wen, X Hu, W Tang, H Wang, L Zhou, L Wu, H Wang, C Xu, X Xu, Z Xiao, Z Li, C Li, Y Liu, J Duan, C Chen, D Li, R Zhang, J Li, Y Yi, W Huang, Y Chen, J Zhao, J Zuo, J Weng, H Jiang, DW Wang. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial. Front Med 2021; 15( 5): 704– 717
https://doi.org/10.1007/s11684-021-0853-6
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed